Agenzia Italiana del Farmaco
Transparency Lists
On this page you can find the list of medicinal products and the relative reference prices including the reduction foreseen pursuant to the AIFA Resolution of 3 July 2006, the further reduction of 5% pursuant to the AIFA Resolution of 27 September 2006, art. 9 paragraph 1, of Law No. 31 of 28 February 2008 (payback) and paragraph 9 of article 11 of Legislative Decree 78/2010 converted with amendments by Law No. 122 of 30 July 2010.
AIFA publishes the lists, in order to allow the Regions and Autonomous Provinces a homogeneous application of the provisions of art. 9, paragraph 5 of Law No. 178 of 8 August 2002.
-
List by active ingredient (October 15, 2025) [3.16 Mb] [PDF] >
-
List by commercial name (October 15, 2025) [2.89 Mb] [PDF] >
-
List in table format (October 15, 2025) [1.89 Mb] [XLS] >
-
List in .csv format (October 15, 2025) [1.61 Mb] [CSV] >
-
New groups included in the transparency list (October 15, 2025) [0.42 Mb] [PDF] >
-
Disposizioni AIFA su modalità di rimborso e prescrizione per le specialità a base di calcipotriolo e betametasone (15/09/2023) [0.1 Mb] [PDF] >
-
Determinazione DG/295/2022 - Modifica alla Determinazione DG/166/2021 [0.21 Mb] [PDF] >
-
FAQ - Definizione dei criteri per l'inserimento in lista di trasparenza dei medicinali (aggiornamento del 23/02/2021) [0.16 Mb] [PDF] >
-
Determinazione DG/88/2022 - Definizione dei criteri per l'inserimento in lista di trasparenza [0.23 Mb] [PDF] >
-
Determina 166/2021 - Definizione dei criteri per l'inserimento in lista di trasparenza [5.29 Mb] [PDF] >
-
AIFA provisions on reimbursement and prescription methods for Calcipotriol and Betamethasone-based specialties (15/10/2020) [0.08 Mb] [PDF] >
-
Disposizioni AIFA su modalità di rimborso e prescrizione per le specialità a base di calcipotriolo e betametasone (15/10/2020) [0.08 Mb] [PDF] >
-
Prescribing and of dispensing of pregabalin-based equivalent medicines for the treatment of neuropathic pain (July 13, 2017) [0.09 Mb] [PDF] >
-
Press release for irbesartan and irbesartan/hydrochlorothiazide-based medicinal products (16/11/2016) [0.13 Mb] [PDF] >
-
Reimbursement and prescription procedures for cyclosporine-based medicinal products (January 19, 2016) [0.08 Mb] [PDF] >
-
AIFA clarifications on medicinal products containing cyclosporine (April 15, 2015) [0.16 Mb] [PDF] >
-
AIFA communication on medicinal products containing Levetiracetam and Topiramate (September 17, 2012) [0.12 Mb] [PDF] >
-
AIFA clarifications on medicinal products containing tacrolimus (July 22, 2011) [0.03 Mb] [PDF] >
